TY - JOUR
T1 - Apoe ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias
AU - Lovati, Carlo
AU - Galimberti, Daniela
AU - Albani, Diego
AU - Bertora, Pierluigi
AU - Venturelli, Eliana
AU - Cislaghi, Giuliana
AU - Guidi, Ilaria
AU - Fenoglio, Chiara
AU - Cortini, Francesca
AU - Clerici, Francesca
AU - Finazzi, Dario
AU - Forloni, Gianluigi
AU - Scarpini, Elio
AU - Mariani, Claudio
PY - 2010
Y1 - 2010
N2 - Apolipoprotein E (APOE) genotype was determined in a population of patients with dementia, including 735 patients with Alzheimer's disease (AD), 75 with Frontotemporal Lobar Degeneration (FTLD), 97 with Vascular Dementia (VaD) and 40 with Lewy Body Dementia (LBD), as well as in 506 age-and gender-matched controls (CON). APOE ε2 allele frequency was lower in patients with AD (2.8%) than in CON (6.4%, P≤0.001, OR: 0.41). Similar results were obtained comparing AD with FTLD (6.7%, P≤0.01, OR: 0.37), at difference from VaD (5.6%, P>0.05) or LBD (5.0%, P>0.05). The frequency of the APOE ε4 allele was increased in patients with AD (25.1%) as compared with CON (8.2%, P≤0.001, OR: 4.24), FTLD (11.3%, P≤0.001, OR: 2.67), VaD (11.8%, P≤0.001, OR: 3.02), or LBD (13.8%, P=0.048, OR: 2.07). The frequency of the ε4/ε4 genotype was increased in AD patients compared with controls (6.3 versus 0.8%, P≤0.001, OR: 8.38). The presence of the ε2 allele is a protective factor for AD, whereas the ε4 allele acts as a risk factor for the disease. Both alleles do not influence the susceptibility to FTLD, LBD and VaD.
AB - Apolipoprotein E (APOE) genotype was determined in a population of patients with dementia, including 735 patients with Alzheimer's disease (AD), 75 with Frontotemporal Lobar Degeneration (FTLD), 97 with Vascular Dementia (VaD) and 40 with Lewy Body Dementia (LBD), as well as in 506 age-and gender-matched controls (CON). APOE ε2 allele frequency was lower in patients with AD (2.8%) than in CON (6.4%, P≤0.001, OR: 0.41). Similar results were obtained comparing AD with FTLD (6.7%, P≤0.01, OR: 0.37), at difference from VaD (5.6%, P>0.05) or LBD (5.0%, P>0.05). The frequency of the APOE ε4 allele was increased in patients with AD (25.1%) as compared with CON (8.2%, P≤0.001, OR: 4.24), FTLD (11.3%, P≤0.001, OR: 2.67), VaD (11.8%, P≤0.001, OR: 3.02), or LBD (13.8%, P=0.048, OR: 2.07). The frequency of the ε4/ε4 genotype was increased in AD patients compared with controls (6.3 versus 0.8%, P≤0.001, OR: 8.38). The presence of the ε2 allele is a protective factor for AD, whereas the ε4 allele acts as a risk factor for the disease. Both alleles do not influence the susceptibility to FTLD, LBD and VaD.
KW - Alzheimer's disease (AD)
KW - Apolipoprotein E (APOE)
KW - Frontotemporal lobar degeneraton (FTLD)
KW - Lewy body dementia (LBD)
KW - Risk factor
KW - Vascular dementia (VaD)
UR - http://www.scopus.com/inward/record.url?scp=77955681224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955681224&partnerID=8YFLogxK
M3 - Article
C2 - 21537391
AN - SCOPUS:77955681224
SN - 1948-1756
VL - 1
SP - 193
EP - 200
JO - International Journal of Molecular Epidemiology and Genetics
JF - International Journal of Molecular Epidemiology and Genetics
IS - 3
ER -